Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx™ and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx™GlobeNewsWire • 05/01/20
OncoCyte Corporation (OCX) CEO Ronald Andrews on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/26/20
Oncocyte Announces the Launch of CLIA-validated DetermaIO™, a Novel Gene Expression-Based Immune Therapy Response Predictor, for Research Use by Biopharmaceutical Companies and ResearchersGlobeNewsWire • 03/19/20
OncoCyte Enters Into The Cancer Immunotherapy Field With The Acquisition Of Insight GeneticsSeeking Alpha • 01/23/20
Oncocyte Announces the Commercial Availability of DetermaRx™, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small Cell Lung CancerGlobeNewsWire • 01/13/20
OncoCyte Meets An Important Milestone With The Completion Of CLIA Validation Of DetermaDxSeeking Alpha • 01/10/20
OncoCyte Announces Successful Completion of CLIA Validation Study of DetermaDx™GlobeNewsWire • 01/07/20
OncoCyte Corporation (OCX) CEO Ronald Andrews on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/15/19
OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019GlobeNewsWire • 10/15/19
OncoCyte Corporation (OCX) CEO Ronald Andrews on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/15/19
OncoCyte Corporation (OCX) CEO William Annett on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/15/19
OncoCyte Corporation (OCX) CEO William Annett on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 04/02/19